컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

American Heart Association (AHA) Scientific Sessions 2025

07 November - 10 November, 2025, United States

Long-term melatonin use may put heart at risk

2025-12-10

Long-term supplementation (≥12 months) with melatonin is associated with a higher risk of incident heart failure (HF) diagnosis, hospitalization for HF (HHF), and all-cause mortality in individuals with chronic insomnia in a large retrospective review of electronic health records (EHRs) presented at AHA 2025.
Systematic review supports etripamil for PSVT treatment

2025-12-10

A systemic review presented at AHA 2025 demonstrates the potential of etripamil nasal spray as a patient-administered therapy for paroxysmal supraventricular tachycardia (PSVT), which may reduce reliance on emergency care.
Is coffee proarrhythmic? New data suggest otherwise

2025-12-10

For adults treated for persistent atrial fibrillation (AF), drinking a cup of coffee every day does not trigger AF recurrence or atrial flutter and even appears to reduce its incidence, according to the DECAF trial.
Patients without prior MI or stroke get cardioprotection from evolocumab

2025-12-10

The PCSK9 inhibitor evolocumab, when added to background lipid-lowering therapy, helps reduce the risk of major adverse cardiovascular events in patients with atherosclerosis or diabetes who have no history of myocardial infarction (MI) or stroke, according to the randomized VESALIUS-CV trial.
Polypill approach shows promise in HFrEF

2025-12-10

Once-daily polypill, a single encapsulated pill containing three guideline-directed medical therapy (GDMT) classes (metoprolol succinate, empagliflozin, and spironolactone), is associated with improved outcomes in patients with heart failure with reduced ejection fraction (HFrEF), according to the POLY-HF trial presented at AHA 2025.
Osimertinib linked to cardiac events in NSCLC patients

2025-12-10

Patients with non-small cell lung cancer (NSCLC) treated with osimertinib have a higher risk of QT prolongation, reduced ejection fraction, and high-grade cardiac failure than those who received placebo or other standard therapies, reports a study.
Tirzepatide trims risk of major adverse cardiovascular events

2025-12-10

Treatment with tirzepatide 15 mg/week results in a 33-percent reduction in the risk of major adverse cardiovascular events (MACE), results of a meta-analysis have shown. Moreover, its efficacy is consistent across individuals with or without obesity.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2026 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브